2025.04.17 -

Caliway Selected to Present CBL-514 Phase 2 Study Results for Dercum’s Disease at World Orphan Drug Congress USA 2025

CBL-514, Caliway’s novel small molecule drug, was selected for data presentation at the World Orphan Drug Congress USA 2025, highlighting its promising Phase 2 study results for Dercum’s Disease Treatment.

2025.03.20 -

Caliway Selected to Present CBL-514 Phase 2b Study Results at AMWC 2025 in Monaco

Caliway’s localized fat reduction drug, CBL-514, has been selected for presentation at the globally renowned AMWC Aesthetic & Anti-Aging Medicine World Congress under the "Body & Fat Treatment" session, highlighting CBL-0204 Phase 2b study results.

Caliway’s CBL-514 Phase 2 Study (CBL-0202) Accepted for Publication in the Aesthetic Surgery Journal

CBL-514 Phase 2 study (CBL-0202) has been accepted for publication in Aesthetic Surgery Journal (ASJ).

2025.02.12 -

Caliway Biopharmaceuticals Added to MSCI World Small Cap Index, Reinforcing Global Standing

Caliway has been added to the MSCI World Small Cap Index, as announced today by MSCI (Morgan Stanley Capital International) in its latest quarterly review.

2025.02.09 -

Caliway Announces CBL-514 Second Phase 2b Study Results (CBL-0205) Met Endpoints

Caliway announced today that CBL-514’s second Phase 2b clinical study (CBL-0205) successfully met its primary and all critical secondary efficacy endpoints.

2025.02.03 -

Caliway Presented CBL-0204 Phase 2b Study Results of CBL-514 at IMCAS 2025 in Paris

Innovative Non-Surgical Fat Reduction Treatment Gains International Attention

2024.12.19 -

Caliway to Present CBL-514 Phase 2b Study Results for Subcutaneous Fat Reduction at IMCAS 2025 in Paris

The findings from the CBL-0204 Phase 2b clinical trial have been selected for presentation at IMCAS, the premier global congress in aesthetic medicine. The data will be highlighted in both the 2025 focus session on advances in fat reduction therapies and further detailed in the Non-surgical Body Contouring session through an oral presentation.

2024.12.11 -

Caliway Announces Successful Study Results from CBL-0204, a CBL-514 Phase 2b Study for Reducing Abdominal Subcutaneous Fat, Met All Primary and Secondary Efficacy Endpoints

CBL-514 Phase 2b study for subcutaneous fat reduction (CBL-0204 Phase 2b study) met all the primary and secondary efficacy endpoints in the FAS (Full analysis set) and PP (Per-protocol) population analysis.